Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ctr.14624 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Letermovir for prevention of recurrent CMV in high-risk allogeneic hematopoietic cell transplant (HCT) recipients.
Transplant Cell Ther
December 2024
Infectious Diseases Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:
Background: We evaluated letermovir (LTV) for secondary prophylaxis for cytomegalovirus (CMV) in allogeneic hematopoietic cell transplant recipients (HCT) at high-risk for CMV recurrence.
Methods: Open-label study conducted at Memorial Sloan Kettering Cancer Center and the University of Minnesota. Patients with clinically significant CMV infection (cs-CMVi) and ≥1 high-risk criteria for CMV who achieved viral suppression with standard CMV antivirals, received letermovir (LTV) secondary prophylaxis for up to 14 weeks.
Effectiveness of letermovir in preventing cytomegalovirus reactivation after cord blood transplantation.
J Infect Chemother
December 2024
Department of Hematology/Oncology, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, 710-8602, Japan.
Article Synopsis
- Cord blood transplantation (CBT) has a high risk of cytomegalovirus (CMV) infection, and Letermovir (LTV) is an effective drug for preventing CMV reactivation after CBT.
- A study involving 79 adult patients revealed that those who received LTV had significantly lower rates of CMV reactivation compared to those who did not, with 11.1% versus 82.4% at day 100 and 45.3% versus 82.4% at one year.
- Despite the lower reactivation rates, approximately 34.2% of patients experienced late CMV reactivation after stopping LTV, suggesting the need for ongoing monitoring and potential extension of LTV use
Letermovir prophylaxis for cytomegalovirus is associated with risk of post-transplant lymphoproliferative disorders after haploidentical stem cell transplantation.
Haematologica
November 2024
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Peking-Tsinghua Center for Life Sciences, Beijing.
Not available.
View Article and Find Full Text PDFImpact of Letermovir for Cytomegalovirus Primary Prophylaxis on Myelosuppression and Immunosuppression in Lung Transplant Recipients.
Clin Transplant
December 2024
Division of Pulmonary and Critical Care, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Background: Cytomegalovirus (CMV) is associated with detrimental outcomes after lung transplantation (LTX); primary prophylaxis (PPX) with valganciclovir (VGC) is guideline-recommended. VGC is associated with myelosuppression, spurring interest in letermovir (LTV).
Methods: Adults undergoing LTX between January 1, 2021, and July 30, 2022 at our institution who were converted from VGC to LTV for PPX were evaluated.
CMV-Related Hemorrhagic Retinal Vasculitis in a Multiple Myeloma Patient on Daratumumab Therapy: A Case Report.
Ocul Immunol Inflamm
November 2024
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
Purpose: To report a case of cytomegalovirus (CMV)-related hemorrhagic retinal vasculitis in a patient with multiple myeloma (MM) on daratumumab, a trial cereblon E3 ligase modulatory drug (CELMoD), dexamethasone, and acyclovir, and discuss clinical implications for CMV prophylaxis.
Methods: Case report, narrative review of CMV reactivation risk in MM patients on daratumumab and antiviral agent efficacy for CMV prophylaxis.
Results: A 63-year-old female presented with 3 days of progressive unilateral vision loss in the right eye to the level of counting fingers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!